TNF-α down-regulates sarcoplasmic reticulum Ca2+ ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-κB to promoter response element

Cardiovascular Research

Volumn 105, Issue 3, 2015, Pages 318-329

  Tsai, Chia Ti ^a,b   Wu, Cho Kai ^a,b   Lee, Jen Kuang ^a,b   Chang, Sheng Nan ^a,b   Kuo, Yu Min ^a,b   Wang, Yi Chih ^a   Lai, Ling Ping ^a   Chiang, Fu Tien ^a   Hwang, Juey Jen ^a   Lin, Jiunn Lee ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Atp2a2; Diastolic dysfunction; SERCA2a; Simvastatin; TNF ; Transcription

Indexed keywords

CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ETANERCEPT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LUCIFERASE; MESSENGER RNA; PYRROLIDINE DITHIOCARBAMATE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ATP2A2 PROTEIN, RAT; PROTEIN BINDING;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; GEL MOBILITY SHIFT ASSAY; GENE REPRESSION; HEART FUNCTION; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LUCIFERASE ASSAY; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TISSUE DOPPLER IMAGING; TRANSCRIPTION INITIATION SITE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICALLY INDUCED; DIASTOLE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEART LEFT VENTRICLE FUNCTION; INFLAMMATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; CELL LINE; DIASTOLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MYOCYTES, CARDIAC; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RATS, WISTAR; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84937940107     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv008     Document Type: Article

References (41)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259.
2. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003;41:1519-1522.
3. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J 2012;33:1750-1757.
4. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004;95: 1140-1153.
5. 2+ ATPase. Crit Care Med 2011;39:984-992.
6. Lin CY, Wu CK, Yeong EK, Lin HH, Huang YT, Lee JK, Lin YH, Chiang FT, Tang YB, Tsai CT. Prognostic significance of left ventricular diastolic function in burn patients. Shock 2012;37:457-462.
7. Lee JK, Lin HH, Tsai CT, Chen JJ, Kuo CC, Lien YC, Lin JW, Huang JW, Hwang SW, Hwang JJ, Tseng CD, Chiang FT, Wu CK. Differential association of proinflammatory cytokines with left ventricular diastolic dysfunction in subjects with and without continuous ambulatory peritoneal dialysis. Nutr Metab Cardiovasc Dis 2012;22:974-980.
8. Periasamy M, Huke S. Serca pump level is a critical determinant of Ca(2+) homeostasis and cardiac contractility. J Mol Cell Cardiol 2001;33:1053-1063.
9. Tsai CT, Wang DL, ChenWP, Hwang JJ, Hsieh CS, Hsu KL, Tseng CD, Lai LP, Tseng YZ, Chiang FT, Lin JL. Angiotensin II increases expression of alpha1c subunit of l-type calcium channel through a reactive oxygen species andcAMP response element-binding proteindependent pathway in HL-1 myocytes. Circ Res 2007;100:1476-1485.
10. Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, Tseng CD, Tseng YZ, Chiang FT, Lin JL. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008;117:344-355.
11. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther 1992;260: 748-755.
12. Xu T, Wang T, Han JS. Centrally acting endogenous hypotensive substances in rats subjected to endotoxic shock. Life Sci 1992;51:1817-1821.
13. Mitra R, Morad M. Auniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am J Physiol 1985;18:H1056-H1060.
14. Li J, Yin Q, Wu H. Structural basis of signal transduction in theTNF receptor superfamily. Adv Immunol 2013;119:135-153.
15. Chu WM. Tumor necrosis factor. Cancer Lett 2013;328:222-225.
16. Ahn J, Kim J. Mechanisms and consequences of inflammatory signaling in the myocardium. Curr Hypertens Rep 2012;14:510-516.
17. Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys 2013;42: 443-468.
18. Liedtke C, Trautwein C. The role of TNFand Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. Eur J Cell Biol 2012;91:582-589.
19. Verhelst K, Carpentier I, Beyaert R. Regulation of TNF-induced NF-kappaB activation by different cytoplasmic ubiquitination events. Cytokine Growth Factor Rev 2011;22: 277-286.
20. Kretzmann NA, Chiela E, Matte U, Marroni N, Marroni CA. N-acetylcysteine improves antitumoural response of interferon alpha by NF-kB downregulation in liver cancer cells. Comp Hepatol 2012;11:4.
21. Flesch M, Schiffer F, Zolk O, Pinto Y, Stasch JP, Knorr A, Ettelbruck S, Bohm M. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 1997;15:1001-1009.
22. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, HoffmannW, PollerW, Schultheiss HP, Pauschinger M, Tschope C. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: A comparative Doppler-conductance catheterization study. Circulation 2007;116:637-647.
23. Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, Lam PK, Sanderson JE. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol 2003;41:820-826.
24. HasegawaH, Little WC, Ohno M, Brucks S, Morimoto A, Cheng HJ, Cheng CP. Diastolic mitral annular velocity during the development of heart failure. J AmColl Cardiol 2003;41: 1590-1597.
25. Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H, Sekikawa K, Seishima M. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol 2002;39:1229-1235.
26. Xu H, Yao Y, Su Z, Yang Y, Kao R, Martin CM, Rui T. EndogenousHMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-alpha and JNK. Am J Physiol Heart Circ Physiol 2011;300:H913-H921.
27. Li YY, Feng YQ, Kadokami T, McTiernan CF, DraviamR, Watkins SC, Feldman AM. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor a can be modulated by anti-tumor necrosis factor a therapy. Proc Natl Acad Sci USA 2000;97:12746-12751.
28. Boltzen U, Eisenreich A, Antoniak S, Weithaeuser A, Fechner H, Poller W, Schultheiss HP, Mackman N, Rauch U. Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-alpha-induced apoptosis. J Mol Cell Cardiol 2012;52:1056-1065.
29. 2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med 2010;38:217-222.
30. Shiraki A, Oyama J, Komoda H, AsakaM, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012;221:375-382.
31. Ock S, Ahn J, Lee SH, Park H, Son JW, Oh JG, Yang DK, Lee WS, Kim HS, Rho J, Oh GT, Abel ED, Park WJ, Min JK, Kim J. Receptor activator of nuclear factor-kappaB ligand is a novel inducer of myocardial inflammation. Cardiovasc Res 2012;94:105-114.
32. Wahlquist C, Jeong D, Rojas-Muñoz A, Kho C, Lee A, Mitsuyama S, van-Mil A, Park WJ, Sluijter JP, Doevendans PA, Hajjar RJ, Mercola M. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014;508:531-535.
33. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E, Park WJ, Hajjar RJ. SUMO1- dependent modulation of SERCA2aa in heart failure. Nature 2011;477:601-605.
34. Mannheim D, Herrmann J, Bonetti PO, Lavi R, Lerman LO, Lerman A. Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis 2011;216:283-291.
35. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebocontrolled trial. Lancet 2008;372:1231-1239.
36. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van-Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
37. Fukuta H, Little WC. Observational studies of statins in heart failure with preserved systolic function. Heart Fail Clin 2008;4:209-216.
38. Zhang J, Xu Y, Pan L, Chen T, Chen Z, Zhao R. Effect of simvastatin on collagen I deposition in non-infarcted myocardium: role of NF-kappaB and osteopontin. Can J Physiol Pharmacol 2010;88:1026-1034.
39. Kang BY, Mehta JL. Rosuvastatin attenuates ang II-mediated cardiomyocyte hypertrophy via inhibition of lox-1. J Cardiovasc Pharmacol Ther 2009;14:283-291.
40. Martin Knöfler M, Kiss H, Mösl B, Egarter C, Husslein P. Interleukin-1 stimulates tumor necrosis factor-a (TNF-a) release from cytotrophoblasticBeWocells independently of induction of the TNF-a mRNA. FEBS Lett 1997;405:213-218.
41. Wu CK, Yang CY, Lin JW, Hsieh HJ, Chiu FC, Chen JJ, Lee JK, Huang SW, Li H Y, Chiang FT, Tsai CT. The relationship among central obesity, systemic inflammation, and left ventricular diastolic dysfunction as determined by structural equation modeling. Obesity (Silver Spring) 2012;20:730-737.